Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

79
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
79
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mineralocorticoid Antagonists for Post-MI HFpEF: Plausible Biology Meets Low Residual Risk?

The American journal of medicine·2026
Same author

The Role of Implicit Bias in Shaping Medication Prescribing Practices: A Scoping Review.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II.

JACC. Heart failure·2026
Same author

The impact of data source on real-world medication adherence and exposure measures: From prescription to sold.

Journal of managed care & specialty pharmacy·2026
Same author

Rapid quantitative urinary chloride sensing with conductivity correction for cardiac patient management.

Biosensors & bioelectronics·2026
Same author

Patient and Clinician Attitudes Toward Mobile Health Apps: Qualitative Study.

JMIR mHealth and uHealth·2026
Same journal

Achieving Equity in Generative Artificial Intelligence in Cardiovascular Medicine.

JACC. Advances·2026
Same journal

Real-World Experience With a Novel Intravascular Hertz Contact Lithotripsy Balloon in Severely Calcified Coronary Lesions.

JACC. Advances·2026
Same journal

Trends in Cardiac Arrest Mortality Among Young Adults in the United States, 1999 to 2024.

JACC. Advances·2026
Same journal

Pulmonary Hypertension in Adults With a Systemic Right Ventricle (Biventricular Circulation).

JACC. Advances·2026
Same journal

Cholesterol Perceptions and Preferences Among Young Adults: A Survey of U.S. Adults Aged 30 to 39 Years.

JACC. Advances·2026
Same journal

Radiomics for the Detection and Prediction of Cancer Therapy-Related Cardiotoxicity.

JACC. Advances·2026
查看所有相关文章

相关实验视频

Updated: Jun 22, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K

一个可计算的算法,用于心力衰竭中药物优化,减少喷射分数.

Michael P Dorsch1,2, Aaron Sifuentes3, David J Cordwin1

  • 1Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

JACC. Advances
|June 28, 2024
PubMed
概括
此摘要是机器生成的。

一个新的算法可以优化心力衰竭患者的指南导向医学治疗 (GDMT). 较高的药物优化得分 (MOS) 与更好的临床结果有关,这表明改善心力衰竭护理的潜力.

关键词:
可计算的知识知识.数字健康数字健康医疗技术 医疗技术 医疗技术心脏衰竭是因为心脏衰竭.质量和结果.声明和指导方针 声明和指导方针

更多相关视频

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

760
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K

相关实验视频

Last Updated: Jun 22, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.4K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

760
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

1.8K

科学领域:

  • 心脏病学 心脏病学
  • 医疗信息学 医疗信息学
  • 临床试验 临床试验

背景情况:

  • 优化指南导向医学疗法 (GDMT) 对于改善心力衰竭患者的治疗结果至关重要,心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭患者心力衰竭
  • 在临床实践中,低于最佳的GDMT是一个常见的挑战,即使在结构化的临床试验中也是如此.

研究的目的:

  • 评估一个设计用于推HFrEF的GDMT的新型可计算算法.
  • 评估算法的建议是否与实际的药物调整保持一致,以及它的输出是否与患者的结果相关.

主要方法:

  • 利用来自GUIDE-IT和HF-ACTION研究的临床试验数据.
  • 应用了一个可计算的药物优化算法来生成GDMT建议和药物优化得分 (MOS).
  • 将基于算法的建议与实际的药物变化进行了比较,并使用Cox比例危险模型分析了MOS和临床终点之间的关联.

主要成果:

  • 该算法确定了在试验中未充分利用的GDMT (ACEI/ARB,β-阻断剂,MRA) 的启动和定位的重大机会.
  • 较高的基线MOS与降低心血管死亡或心力衰竭住院的风险显著相关,在GUIDE-IT (HR:0.41) 和所有原因死亡/住院在HF-ACTION (HR:0.61).
  • 该算法在识别可能从GDMT优化中受益的患者方面表现得精确.

结论:

  • 可计算的算法有效地识别了需要在HFrEF中优化GDMT的患者.
  • 算法生成的MOS是改善临床结果的预测指标,突出其潜在的临床实用性.
  • 在临床环境中实施该算法可以解决低于最佳的GDMT,并改善HFrEF患者的护理.